Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

What are the long-term outcomes for early-stage HL patients who received radiotherapy alone or combined with chemotherapy?

Posted by on Feb 15, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined long-term risk of death from all causes using data from 1,541 early-stage (stage 1-2) Hodgkin’s lymphoma (HL) patients who received radiotherapy (RT) alone or RT with chemotherapy. This study concluded that this risk was significantly lower for patients treated in the most recent era of radiation therapy thanks...

Read More

What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?

Posted by on Feb 9, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...

Read More

What are the real-world outcomes for ASCT-ineligible patients with refractory or relapsed HL who are given brentuximab vedotin?

Posted by on Feb 5, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the real-world outcomes for patients with relapsed or refractory Hodgkin’s lymphoma (rrHL) who were given brentuximab vedotin (Adcetris) due to ineligibility for autologous stem cell transplant (ASCT). The study concluded that brentuximab vedotin is feasible and effective in patients with rrHL who are...

Read More

Combined haploidentical-cord stem cell transplantation in lymphoma and CLL – what are the outcomes?

Posted by on Jan 30, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...

Read More

To Treat or Not To Treat Cancer: Medical Decision-making

To Treat or Not To Treat Cancer: Medical Decision-making

Posted by on Jan 28, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma | 3 comments

Cherry Hughes** is an active, energetic 75 year old, still working in the marketing and public relations profession in Great Britain.  Her life is filled with friends and fun.  “I love cooking and eating out.  I am deeply interested in politics.  I love music …I go to jazz clubs.  I love going to France …I have a little apartment...

Read More

What is Neutropenia?

What is Neutropenia?

Posted by on Jan 21, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

There are 1.6 million people diagnosed with cancer in the US each year. Of these, 650,000 receive chemotherapy. Did you know that 60,000 people a year are hospitalized for neutropenia, a common side effect of chemotherapy? One in fourteen die because of it. Of the 650,000 receiving chemotherapy, 104,000 are not aware of neutropenia and 52,000 don’t...

Read More

Emergencies and Illness

Emergencies and Illness

Posted by on Jan 17, 2018 in Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Hodgkin's lymphoma, Hypertension, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Prostate cancer | 1 comment

After three hurricanes, flooding, fires and mudslides, and now severe cold and snow in the Deep South and throughout the country, the US has had its share of emergencies. Are you prepared? For people who rely on oxygen, who are on dialysis, have diabetes or other serious conditions, it is time to think about putting together some of the essentials.  What...

Read More

What are the outcomes for early-stage HL patients treated with ABVD and radiotherapy alone?

Posted by on Jan 16, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the outcomes of early-stage classical Hodgkin’s lymphoma (HL) patients who received ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy and radiotherapy (RT) only. The study concluded that patients who showed a good partial response (tumor shrinkage) to ABVD chemotherapy were successfully...

Read More

Brentuximab vedotin plus nivolumab to treat patients with relapsed or refractory Hodgkin lymphoma

Posted by on Jan 12, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) to treat patients with relapsed or difficult to treat Hodgkin lymphoma. The study concluded that the combination of brentuximab vedotin and nivolumab is an effective treatment for patients with relapsed Hodgkin lymphoma.  Some...

Read More